• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Boston Life Sciences, Inc. Announces Appointment of Chief Medical Officer

Posted on: Wednesday, 5 October 2005, 09:00 CDT

Boston Life Sciences, Inc., (NASDAQ: BLSI), a biotechnology company focused on diagnostic and therapeutic products for diseases of the Central Nervous System (CNS), today announced the appointment of Mark R. Hurtt, M.D., to the position of Chief Medical Officer.

"Mark brings a wealth of knowledge, experience and energy to Boston Life Sciences. He has been involved with the clinical and regulatory approval programs of CNS products in the pharmaceutical industry for many years," said Dr. Mark Pykett, President and COO of BLSI. "His depth of experience in drug development should add immediate value to our late-stage molecular imaging program for ALTROPANE in Parkinson's disease and ADHD and should accelerate the progress of our stroke and Parkinson's Disease therapy programs. Under his direction, we expect Mark will help guide the efficient, focused clinical development plans for our pre-clinical candidates and assist in the evaluation of new CNS pipeline opportunities."

Most recently, Dr. Hurtt was Senior Director of Clinical Research at Neurogen Corporation (Branford, CT). Prior to Neurogen, Mark was Director of Drug Development and Director of Clinical Research at Pfizer Global Research and Development in Ann Arbor, MI. During his career, Dr. Hurtt has overseen CNS development programs in Parkinson's Disease, Alzheimer's disease, schizophrenia, pain, anxiety and depression. Dr. Hurtt is Board certified in Neurology and Neuropathology. He received his medical degree from Jefferson Medical College and served as a Medical Officer in the United States Navy. He trained in neurology and neuropathology and was an assistant professor in the Departments of Neurology and Pathology at the University of Pittsburgh.

About Boston Life Sciences, Inc.

Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, O-1369 for the treatment of Parkinson's disease and FLUORATEC(TM), a second generation molecular imaging agent, for PS and ADHD. BLSI's current research collaborations include Harvard Medical School, Children's Hospital of Boston and the University of Massachusetts-Worcester.

ALTROPANE is a registered trademark of Boston Life Sciences, Inc.

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future, including the Company's development efforts regarding the Company's ALTROPANE program and the Company's pre-clinical candidates. Forward-looking statements can be identified by terminology such as "anticipate,""believe,""could,""could increase the likelihood,""estimate,""expect,""intend,""is planned,""may,""should,""will,""will enable,""would be expected,""look forward,""may provide,""would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on form 10-Q for the quarter ended June 30, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences, Inc. is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Source: Business Wire

More News in this Category